http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
초산 당시 아버지의 직장 특성과 둘째 출산의 관계: 복리후생제도와 직무만족도를 중심으로
조현지(Hyeonji Cho),진미정(Meejung Chin) 한국가족정책학회 2024 가족정책연구 Vol.4 No.1
This study examines the relationship between fathers’ workplace characteristics at the time of their first child’s birth and the decision to have a second child within two years thereafter. Employing Bronfenbrenner’s PPCT (Process-Person-Context-Time) model, we classified fathers’ job characteristics into family-friendly job policies, a “context” factor, and job satisfaction as a “process” factor. We pooled data from the Korean Labor and Income Panel Study, utilizing a sample of 919 employed fathers whose first child was born between 2001 and 2019. After adjusting for the year of first childbirth, our logistic regression analysis revealed that fathers who reported higher satisfaction with their working environment during their first child’s birth were more likely to have a second child within two years. We further tested the same analyses among 425 fathers who had their first child after 2011, coinciding with the implementation of the Second National Plan for Low Fertility and Aging Society. Fathers employed at a workplace where a tuition assistance system was available were more likely to have a second child.
다중 RNA의 동시 전달을 위한 지질 나노 전달 시스템
이드보라(Deborah Lee),이지예(Ji Ye Lee),이효정(Hyojeong Lee),조현지(Hyeonji Cho),송서윤(Seoyoon Song),이시은(Sieun Lee),전태준(Tae-Joon Jeon),김선민(Sun Min Kim) 대한기계학회 2024 大韓機械學會論文集B Vol.48 No.7
약물 전달 시스템의 발전에서 리포솜(liposome)은 임상적으로 승인된 제형과 더불어 광범위하게 수용되고 있다. 이와 동시에 핵산 기반 치료법, 특히 메신저 리보 핵산(mRNA)과 짧은 간섭 리보 핵산(siRNA)은 표적화된 개인 맞춤형 의료 치료법을 위한 새로운 길을 열고 있다. 그러나 이를 이용한 효과적인 치료를 위해서는 여러 리보 핵산(RNA)을 동시에 전달할 수 있는 효율적인 전달 시스템을 개발해야 한다. 이에 따라 이 연구에서는 지질 나노입자(LNP)의 장점과 기존 리포솜 전달 시스템을 결합한 다중구조의 전달 시스템을 개발하였다. 다중 LNP는 리포솜의 내부에 캡슐화되어 여러 RNA를 동시에 전달한다. 이 연구는 다중 RNA 전달을 위한 유망한 플랫폼이며 핵산 기반 병용 요법 분야의 발전을 가져올 것으로 예상된다. In the field of drug delivery systems, liposomes have gained widespread acceptance through clinically approved formulations. Concurrently, the domain of nucleic acid-based therapeutics, particularly messenger RNA (mRNA) and small interfering RNA (siRNA), has opened new avenues for targeted and personalized medical interventions. However, realizing their full therapeutic potential depends on the development of efficient delivery systems capable of multi-delivering RNAs. Therefore, this paper presents an innovative approach that merges the advantages of lipid nanoparticles (LNPs) with established liposomal delivery systems. This study underscores a promising platform for multiple RNA delivery and controlled releases, offering the potential for advancements in the field of nucleic acid-based combination therapy.